Samuel C. R. Sherratt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samuel C. R. Sherratt has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ronald Paul Mason
Elucida Research, Beverly, Massachusetts, USA; Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA
14 shared publications - Deepak L. Bhatt
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY (D.L.B.).
11 shared publications - Peter Libby
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA
9 shared publications - Hazem Dawoud
Ohio University, Department of Chemistry and Biochemistry, Athens, OH, United States of America
4 shared publications - Tadeusz Malinski
Ohio University, Department of Chemistry and Biochemistry, Athens, OH, United States of America
3 shared publications Peter Libby
Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (9) , 101664
Rates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins
- 24 August 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (9) , 101664
Open AccessRates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins
- Open Access
- 25 August 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 2014-2026
Eicosapentaenoic acid limits the more rapid oxidation of lipoprotein(a) compared with other apolipoprotein B particles
Aims: Elevated lipoprotein(a) [Lp(a)] levels increase cardiovascular (CV) risk. Lp(a) contains oxidized phospholipids that may promote lipid oxidation more than other lipoproteins. The highly unsaturated omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple double bonds that can trap free radicals in resonance structures. Purified ethyl-EPA reduced CV events in high-risk patients with elevated Lp(a) despite Lp(a)-associated risk elevation. Since Lp(a) is enriched in oxidized lipids, we hypothesized that Lp(a)-enriched plasma undergoes more rapid oxidation than other apolipoprotein B (ApoB)-containing particles and that EPA limits oxidation of Lp(a)-enriched plasma more effectively than less-unsaturated fatty acids or other lipid-lowering treatments. This property could limit the cellular stress responses in endothelial cells (ECs). Methods and results: Lp(a) was enriched to >50% total ApoB content to resemble an Lp(a)-associated ‘high-risk’ phenotype and compared with matching levels of small-dense LDL (sdLDL) and very-low-density lipoprotein by isopycnic centrifugation. Samples were then incubated with EPA (50 µM) or equivolume vehicle at 37°C for 30 min. Oxidation was initiated with copper sulfate and monitored by malondialdehyde formation. We also subjected EPA to oxidation before measuring its antioxidant activity when compared with other long chain, less saturated fatty acids and lipid-lowering agents. Human umbilical vein ECs (HUVECs) were incubated with Lp(a)-enriched plasma following oxidation in the absence and presence of EPA. Cell lysate samples were then analysed by global liquid chromatography-mass spectroscopy (LC/MS)–based proteomics for significant changes in protein expression (>1-fold). Lp(a)-enriched plasma contained the highest baseline oxidized lipid (P < 0.05) and underwent the most rapid oxidation. EPA, but neither the less-unsaturated fatty acids nor lipid agents attenuated oxidation of each fraction through 4 h (P < 0.01). Oxidized EPA had diminished antioxidant capacity corresponding to the extent of oxidation. Attenuation of Lp(a) oxidation with EPA also mitigated pro-inflammatory and cellular stress response changes in protein expression. Conclusions: Lp(a)-enriched plasma underwent more rapid oxidation than other ApoB-containing lipoproteins and promoted inflammatory changes in EC protein expression, a process attenuated by EPA. This action may contribute to reduced CV risk by EPA in those with elevated Lp(a) levels.
- 25 August 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (13) , 2014-2026
Open AccessEicosapentaenoic acid limits the more rapid oxidation of lipoprotein(a) compared with other apolipoprotein B particles
Aims: Elevated lipoprotein(a) [Lp(a)] levels increase cardiovascular (CV) risk. Lp(a) contains oxidized phospholipids that may promote lipid oxidation more than other lipoproteins. The highly unsaturated omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple double bonds that can trap free radicals in resonance structures. Purified ethyl-EPA reduced CV events in high-risk patients with elevated Lp(a) despite Lp(a)-associated risk elevation. Since Lp(a) is enriched in oxidized lipids, we hypothesized that Lp(a)-enriched plasma undergoes more rapid oxidation than other apolipoprotein B (ApoB)-containing particles and that EPA limits oxidation of Lp(a)-enriched plasma more effectively than less-unsaturated fatty acids or other lipid-lowering treatments. This property could limit the cellular stress responses in endothelial cells (ECs). Methods and results: Lp(a) was enriched to >50% total ApoB content to resemble an Lp(a)-associated ‘high-risk’ phenotype and compared with matching levels of small-dense LDL (sdLDL) and very-low-density lipoprotein by isopycnic centrifugation. Samples were then incubated with EPA (50 µM) or equivolume vehicle at 37°C for 30 min. Oxidation was initiated with copper sulfate and monitored by malondialdehyde formation. We also subjected EPA to oxidation before measuring its antioxidant activity when compared with other long chain, less saturated fatty acids and lipid-lowering agents. Human umbilical vein ECs (HUVECs) were incubated with Lp(a)-enriched plasma following oxidation in the absence and presence of EPA. Cell lysate samples were then analysed by global liquid chromatography-mass spectroscopy (LC/MS)–based proteomics for significant changes in protein expression (>1-fold). Lp(a)-enriched plasma contained the highest baseline oxidized lipid (P < 0.05) and underwent the most rapid oxidation. EPA, but neither the less-unsaturated fatty acids nor lipid agents attenuated oxidation of each fraction through 4 h (P < 0.01). Oxidized EPA had diminished antioxidant capacity corresponding to the extent of oxidation. Attenuation of Lp(a) oxidation with EPA also mitigated pro-inflammatory and cellular stress response changes in protein expression. Conclusions: Lp(a)-enriched plasma underwent more rapid oxidation than other ApoB-containing lipoproteins and promoted inflammatory changes in EC protein expression, a process attenuated by EPA. This action may contribute to reduced CV risk by EPA in those with elevated Lp(a) levels.
- Open Access
- 1 November 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (11) , 2258-2263
“A Time to Tear Down and a Time to Mend”: The Role of Eicosanoids in Atherosclerosis
- 1 November 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (11) , 2258-2263
Open Access“A Time to Tear Down and a Time to Mend”: The Role of Eicosanoids in Atherosclerosis
- Open Access
- 16 July 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (14) , e034076
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
Background: Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte activation. Eicosapentaenoic acid (EPA) administered as icosapent ethyl reduced cardiovascular events in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) in relation to on‐treatment EPA blood levels. The mechanisms of cardiovascular protection for EPA remain incompletely elucidated but likely involve direct effects on the endothelium. Methods and Results: In this study, human ECs were treated with EPA and challenged with the cytokine IL‐6 (interleukin‐6). Proinflammatory responses in the ECs were confirmed by ELISA capture of sICAM‐1 (soluble intercellular adhesion molecule‐1) and TNF‐α (tumor necrosis factor‐α). Global protein expression was determined using liquid chromatography–mass spectrometry tandem mass tag. Release kinetics of NO and peroxynitrite were monitored using porphyrinic nanosensors. IL‐6 challenge induced proinflammatory responses from the ECs as evidenced by increased release of sICAM‐1 and TNF‐α, which correlated with a loss of NO bioavailability. ECs pretreated with EPA modulated expression of 327 proteins by >1‐fold ( P P <0.05). Conclusions: These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.
- 16 July 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (14) , e034076
Open AccessEicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
Background: Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte activation. Eicosapentaenoic acid (EPA) administered as icosapent ethyl reduced cardiovascular events in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) in relation to on‐treatment EPA blood levels. The mechanisms of cardiovascular protection for EPA remain incompletely elucidated but likely involve direct effects on the endothelium. Methods and Results: In this study, human ECs were treated with EPA and challenged with the cytokine IL‐6 (interleukin‐6). Proinflammatory responses in the ECs were confirmed by ELISA capture of sICAM‐1 (soluble intercellular adhesion molecule‐1) and TNF‐α (tumor necrosis factor‐α). Global protein expression was determined using liquid chromatography–mass spectrometry tandem mass tag. Release kinetics of NO and peroxynitrite were monitored using porphyrinic nanosensors. IL‐6 challenge induced proinflammatory responses from the ECs as evidenced by increased release of sICAM‐1 and TNF‐α, which correlated with a loss of NO bioavailability. ECs pretreated with EPA modulated expression of 327 proteins by >1‐fold ( P P <0.05). Conclusions: These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (18) , 2884-2901
Do patients benefit from omega-3 fatty acids?
Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV) health and elevated O3FA levels are associated with lower incident risk for CV disease (CVD.) Yet, treatment of at-risk patients with various O3FA formulations has produced disparate results in large, well-controlled and well-conducted clinical trials. Prescription formulations and fish oil supplements containing low-dose mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have routinely failed to prevent CV events in primary and secondary prevention settings when added to contemporary care, as shown most recently in the STRENGTH and OMEMI trials. However, as observed in JELIS, REDUCE-IT, and RESPECT-EPA, EPA-only formulations significantly reduce CVD events in high-risk patients. The CV mechanism of action of EPA, while certainly multifaceted, does not depend solely on reductions of circulating lipids, including triglycerides (TG) and LDL, and event reduction appears related to achieved EPA levels suggesting that the particular chemical and biological properties of EPA, as compared to DHA and other O3FAs, may contribute to its distinct clinical efficacy. In vitro and in vivo studies have shown different effects of EPA compared with DHA alone or EPA/DHA combination treatments, on atherosclerotic plaque morphology, LDL and membrane oxidation, cholesterol distribution, membrane lipid dynamics, glucose homeostasis, endothelial function, and downstream lipid metabolite function. These findings indicate that prescription-grade, EPA-only formulations provide greater benefit than other O3FAs formulations tested. This review summarizes the clinical findings associated with various O3FA formulations, their efficacy in treating CV disease, and their underlying mechanisms of action.
- 1 December 2023
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (18) , 2884-2901
Open AccessDo patients benefit from omega-3 fatty acids?
Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV) health and elevated O3FA levels are associated with lower incident risk for CV disease (CVD.) Yet, treatment of at-risk patients with various O3FA formulations has produced disparate results in large, well-controlled and well-conducted clinical trials. Prescription formulations and fish oil supplements containing low-dose mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have routinely failed to prevent CV events in primary and secondary prevention settings when added to contemporary care, as shown most recently in the STRENGTH and OMEMI trials. However, as observed in JELIS, REDUCE-IT, and RESPECT-EPA, EPA-only formulations significantly reduce CVD events in high-risk patients. The CV mechanism of action of EPA, while certainly multifaceted, does not depend solely on reductions of circulating lipids, including triglycerides (TG) and LDL, and event reduction appears related to achieved EPA levels suggesting that the particular chemical and biological properties of EPA, as compared to DHA and other O3FAs, may contribute to its distinct clinical efficacy. In vitro and in vivo studies have shown different effects of EPA compared with DHA alone or EPA/DHA combination treatments, on atherosclerotic plaque morphology, LDL and membrane oxidation, cholesterol distribution, membrane lipid dynamics, glucose homeostasis, endothelial function, and downstream lipid metabolite function. These findings indicate that prescription-grade, EPA-only formulations provide greater benefit than other O3FAs formulations tested. This review summarizes the clinical findings associated with various O3FA formulations, their efficacy in treating CV disease, and their underlying mechanisms of action.
- Open Access
- 17 May 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (15) , e113-e114
REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?
Samuel C R Sherratt; REDUCE-IT, Biomarkers, and Confirmation Bias: Are We Missing the Forest for the Trees?, European Journal of Preventive Cardiology, , zwad16
- 17 May 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (15) , e113-e114
Open AccessREDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?
Samuel C R Sherratt; REDUCE-IT, Biomarkers, and Confirmation Bias: Are We Missing the Forest for the Trees?, European Journal of Preventive Cardiology, , zwad16
- Open Access
- 4 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (7)
Comparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model
- 4 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (7)
Open AccessComparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model
- Open Access
- 29 December 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (1) , 1-17
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Purpose of Review: The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce residual cardiovascular (CV) risk among statin-treated subjects. The outcome trials have yielded highly inconsistent results, perhaps attributable to variations in dosage, formulation, and composition. In particular, CV trials using icosapent ethyl (IPE), a highly purified ethyl ester of EPA, reproducibly reduced CV events and progression of atherosclerosis compared with mixed EPA/DHA treatments. This review summarizes the mechanistic evidence for differences among n3-FAs on the development and manifestations of atherothrombotic disease. Recent Findings: Large randomized clinical trials with n3-FAs have produced discordant outcomes despite similar patient profiles, doses, and triglyceride (TG)-lowering effects. A large, randomized trial with IPE, a prescription EPA only formulation, showed robust reduction in CV events in statin treated patients in a manner proportional to achieved blood EPA concentrations. Multiple trials using mixed EPA/DHA formulations have not shown such benefits, despite similar TG lowering. These inconsistencies have inspired investigations into mechanistic differences among n3-FAs, as EPA and DHA have distinct membrane interactions, metabolic products, effects on cholesterol efflux, antioxidant properties, and tissue distribution. EPA maintains normal membrane cholesterol distribution, enhances endothelial function, and in combination with statins improves features implicated in plaque stability and reduces lipid content of plaques. Summary: Insights into reductions in residual CV risk have emerged from clinical trials using different formulations of n3-FAs. Among high-risk patients on contemporary care, mixed n3-FA formulations showed no reduction in CV events. The distinct benefits of IPE in multiple trials may arise from pleiotropic actions that correlate with on-treatment EPA levels beyond TG-lowering. These effects include altered platelet function, inflammation, cholesterol distribution, and endothelial dysfunction. Elucidating such mechanisms of vascular protection for EPA may lead to new interventions for atherosclerosis, a disease that continues to expand worldwide.
- 29 December 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (1) , 1-17
Open AccessRole of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Purpose of Review: The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce residual cardiovascular (CV) risk among statin-treated subjects. The outcome trials have yielded highly inconsistent results, perhaps attributable to variations in dosage, formulation, and composition. In particular, CV trials using icosapent ethyl (IPE), a highly purified ethyl ester of EPA, reproducibly reduced CV events and progression of atherosclerosis compared with mixed EPA/DHA treatments. This review summarizes the mechanistic evidence for differences among n3-FAs on the development and manifestations of atherothrombotic disease. Recent Findings: Large randomized clinical trials with n3-FAs have produced discordant outcomes despite similar patient profiles, doses, and triglyceride (TG)-lowering effects. A large, randomized trial with IPE, a prescription EPA only formulation, showed robust reduction in CV events in statin treated patients in a manner proportional to achieved blood EPA concentrations. Multiple trials using mixed EPA/DHA formulations have not shown such benefits, despite similar TG lowering. These inconsistencies have inspired investigations into mechanistic differences among n3-FAs, as EPA and DHA have distinct membrane interactions, metabolic products, effects on cholesterol efflux, antioxidant properties, and tissue distribution. EPA maintains normal membrane cholesterol distribution, enhances endothelial function, and in combination with statins improves features implicated in plaque stability and reduces lipid content of plaques. Summary: Insights into reductions in residual CV risk have emerged from clinical trials using different formulations of n3-FAs. Among high-risk patients on contemporary care, mixed n3-FA formulations showed no reduction in CV events. The distinct benefits of IPE in multiple trials may arise from pleiotropic actions that correlate with on-treatment EPA levels beyond TG-lowering. These effects include altered platelet function, inflammation, cholesterol distribution, and endothelial dysfunction. Elucidating such mechanisms of vascular protection for EPA may lead to new interventions for atherosclerosis, a disease that continues to expand worldwide.
- 15 November 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 146 (20) , E282-E283
Letter by Sherratt Regarding Article, “Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy”
- 15 November 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 146 (20) , E282-E283
Letter by Sherratt Regarding Article, “Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy”
- Open Access
- 21 May 2022
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 182, 102450
A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes
- 21 May 2022
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 182, 102450
Open AccessA biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes